MX2020001080A - Anticuerpos con dominios funcionales en la region del codo entre el dominio variable y constante. - Google Patents
Anticuerpos con dominios funcionales en la region del codo entre el dominio variable y constante.Info
- Publication number
- MX2020001080A MX2020001080A MX2020001080A MX2020001080A MX2020001080A MX 2020001080 A MX2020001080 A MX 2020001080A MX 2020001080 A MX2020001080 A MX 2020001080A MX 2020001080 A MX2020001080 A MX 2020001080A MX 2020001080 A MX2020001080 A MX 2020001080A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antigen binding
- elbow region
- variable
- constant domain
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/069357 WO2019024979A1 (en) | 2017-07-31 | 2017-07-31 | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| PCT/EP2018/070640 WO2019025391A1 (en) | 2017-07-31 | 2018-07-30 | ANTIBODIES HAVING FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN A VARIABLE DOMAIN AND A CONSTANT DOMAIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001080A true MX2020001080A (es) | 2020-08-06 |
Family
ID=59626578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001080A MX2020001080A (es) | 2017-07-31 | 2018-07-30 | Anticuerpos con dominios funcionales en la region del codo entre el dominio variable y constante. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12331108B2 (enExample) |
| EP (1) | EP3661962A1 (enExample) |
| JP (2) | JP7297734B2 (enExample) |
| KR (1) | KR20200032738A (enExample) |
| CN (1) | CN111094341A (enExample) |
| AU (1) | AU2018311032B2 (enExample) |
| BR (1) | BR112019028180A2 (enExample) |
| CA (1) | CA3069265A1 (enExample) |
| EA (1) | EA202090364A1 (enExample) |
| IL (1) | IL272303A (enExample) |
| MX (1) | MX2020001080A (enExample) |
| SG (1) | SG11201911658QA (enExample) |
| WO (2) | WO2019024979A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| BR112020018918A2 (pt) | 2018-03-22 | 2021-01-05 | Surface Oncology, Inc. | Anticorpos anti-il-27 e usos dos mesmos |
| AU2019266042B2 (en) * | 2018-05-10 | 2025-08-07 | Mirabiologics Inc. | Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides |
| MX2020012895A (es) | 2018-05-30 | 2021-05-27 | Inst Res Biomedicine | Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena. |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| EP4100434A1 (en) | 2020-02-03 | 2022-12-14 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| TWI859420B (zh) | 2020-02-26 | 2024-10-21 | 美商維爾生物科技股份有限公司 | 抗sars-cov-2抗體及使用其之方法 |
| WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| EP4135846A1 (en) | 2020-04-14 | 2023-02-22 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| JP2023525039A (ja) | 2020-05-08 | 2023-06-14 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２に対する抗体 |
| WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
| CA3180477A1 (en) | 2020-06-12 | 2021-12-16 | Elizabeth Alexander | Antibody therapies for sars-cov-2 infection |
| EP4217385A2 (en) | 2020-09-28 | 2023-08-02 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 |
| CN112225807B (zh) * | 2020-10-30 | 2021-09-07 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
| JP2023551667A (ja) | 2020-11-23 | 2023-12-12 | ヴィア・バイオテクノロジー・インコーポレイテッド | 抗－インフルエンザ抗体及びその組合せ |
| KR20230135569A (ko) | 2020-11-23 | 2023-09-25 | 비르 바이오테크놀로지, 인코포레이티드 | 인플루엔자 a 바이러스에 대한 항체 |
| WO2022109309A1 (en) | 2020-11-23 | 2022-05-27 | Vir Biotechnology, Inc. | Broadly neutralizing antibodies against influenza neuraminidase |
| WO2022115486A1 (en) | 2020-11-25 | 2022-06-02 | Vir Biotechnology, Inc. | Antibodies that bind to multiple betacoronaviruses |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4271715A4 (en) * | 2020-12-30 | 2024-11-20 | Wuxi Biologics Ireland Limited | MULTI-SPECIFIC ANTIGEN-BINDING PROTEINS |
| CN112877394A (zh) * | 2021-01-27 | 2021-06-01 | 南京大学 | B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用 |
| WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| WO2022236142A2 (en) * | 2021-05-07 | 2022-11-10 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
| AU2022280767A1 (en) | 2021-05-24 | 2024-01-18 | Humabs Biomed Sa | Engineered polypeptides |
| WO2023034866A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | Antibody therapies for sars-cov-2 infection in pediatric subjects |
| WO2023034871A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | High concentration antibody therapies for sars-cov-2 infection |
| CN114934065A (zh) * | 2021-11-25 | 2022-08-23 | 浙江理工大学绍兴生物医药研究院有限公司 | 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用 |
| EP4444758A2 (en) | 2021-12-10 | 2024-10-16 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| US20230416406A1 (en) | 2022-03-10 | 2023-12-28 | Omeros Corporation | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease |
| WO2023201256A1 (en) | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | High dose antibody therapies for sars-cov-2 infection |
| WO2023230448A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Combination immunotherapy for influenza |
| JP2025522295A (ja) | 2022-05-23 | 2025-07-15 | ヒューマブス・バイオメッド・ソシエテ・アノニム | インフルエンザノイラミニダーゼに対する広域中和抗体 |
| WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
| WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| EP4562034A1 (en) | 2022-07-27 | 2025-06-04 | Humabs Biomed SA | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
| WO2024112818A1 (en) | 2022-11-22 | 2024-05-30 | Humabs Biomed Sa | Engineered anti-sars-cov-2 antibodies and uses thereof |
| WO2024118998A2 (en) | 2022-12-01 | 2024-06-06 | Vir Biotechnology, Inc. | Engineered anti-sars-cov-2 antibodies and methods of using the same |
| WO2024215762A1 (en) | 2023-04-10 | 2024-10-17 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| WO2025010424A1 (en) | 2023-07-06 | 2025-01-09 | Vir Biotechnology, Inc. | Antibodies against staphylococcus antigens and methods of using the same |
| WO2025015321A1 (en) | 2023-07-13 | 2025-01-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001270609A1 (en) * | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| WO2005000898A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| EP2626371A1 (en) * | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| ES2525346T3 (es) | 2008-10-22 | 2014-12-22 | Institute For Research In Biomedicine | Métodos para producir anticuerpos a partir de células plasmáticas |
| WO2012088290A2 (en) * | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| US20140235476A1 (en) * | 2012-12-28 | 2014-08-21 | Abbvie, Inc. | Multivalent binding protein compositions and methods for identifying variants of same |
| HK1216894A1 (zh) * | 2012-12-28 | 2016-12-09 | Abbvie Inc. | 多價結合蛋白組合物 |
| US9814784B2 (en) | 2013-01-03 | 2017-11-14 | Celltrion, Inc. | Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same |
| US10526404B2 (en) * | 2015-04-29 | 2020-01-07 | Institute For Research In Biomedicine | Multispecific anti GM-CSF antibodies |
| AU2016277887B2 (en) * | 2015-06-18 | 2022-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunoglobulin single variable domain antibody against RSV prefusion F protein |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| EP3313871A1 (en) | 2015-06-26 | 2018-05-02 | Institute for Research in Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| KR20180085800A (ko) * | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| AU2019266042B2 (en) * | 2018-05-10 | 2025-08-07 | Mirabiologics Inc. | Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides |
-
2017
- 2017-07-31 WO PCT/EP2017/069357 patent/WO2019024979A1/en not_active Ceased
-
2018
- 2018-07-30 EA EA202090364A patent/EA202090364A1/ru unknown
- 2018-07-30 SG SG11201911658QA patent/SG11201911658QA/en unknown
- 2018-07-30 BR BR112019028180-0A patent/BR112019028180A2/pt not_active Application Discontinuation
- 2018-07-30 JP JP2020505231A patent/JP7297734B2/ja active Active
- 2018-07-30 CA CA3069265A patent/CA3069265A1/en active Pending
- 2018-07-30 CN CN201880048796.4A patent/CN111094341A/zh active Pending
- 2018-07-30 US US16/635,506 patent/US12331108B2/en active Active
- 2018-07-30 WO PCT/EP2018/070640 patent/WO2019025391A1/en not_active Ceased
- 2018-07-30 MX MX2020001080A patent/MX2020001080A/es unknown
- 2018-07-30 AU AU2018311032A patent/AU2018311032B2/en active Active
- 2018-07-30 KR KR1020207006050A patent/KR20200032738A/ko active Pending
- 2018-07-30 EP EP18752697.5A patent/EP3661962A1/en active Pending
-
2020
- 2020-01-28 IL IL272303A patent/IL272303A/en unknown
-
2023
- 2023-06-14 JP JP2023097920A patent/JP2023123588A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201911658QA (en) | 2020-03-30 |
| AU2018311032A1 (en) | 2019-12-05 |
| US12331108B2 (en) | 2025-06-17 |
| KR20200032738A (ko) | 2020-03-26 |
| JP7297734B2 (ja) | 2023-06-26 |
| US20200325220A1 (en) | 2020-10-15 |
| JP2020528758A (ja) | 2020-10-01 |
| WO2019025391A1 (en) | 2019-02-07 |
| AU2018311032B2 (en) | 2025-01-23 |
| EA202090364A1 (ru) | 2020-06-26 |
| IL272303A (en) | 2020-03-31 |
| WO2019025391A9 (en) | 2020-02-13 |
| JP2023123588A (ja) | 2023-09-05 |
| EP3661962A1 (en) | 2020-06-10 |
| CN111094341A (zh) | 2020-05-01 |
| WO2019024979A1 (en) | 2019-02-07 |
| CA3069265A1 (en) | 2019-02-07 |
| BR112019028180A2 (pt) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001080A (es) | Anticuerpos con dominios funcionales en la region del codo entre el dominio variable y constante. | |
| ZA202100676B (en) | Anti-tigit antibody and uses thereof | |
| CY1124118T1 (el) | Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| MX2024015844A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| SA522431756B1 (ar) | Tigit أجسام مضادة لـ | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| EA201890655A1 (ru) | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул | |
| PE20180950A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
| PH12019500571A1 (en) | Anti-pd-1 antibodies | |
| EA201891992A1 (ru) | Химерные рецепторы и способы их применения | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| ZA201807920B (en) | Anti¿gitr antibodies and uses thereof | |
| PH12020550025A1 (en) | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof | |
| MX2023009022A (es) | Anticuerpos multiespecificos con especificidad para ror1 y cd3. | |
| PL422231A1 (pl) | Komórki immunologiczne CAR do leczenia nowotworów | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
| BR112018073660A2 (pt) | anticorpos anti-fator ix pádua | |
| MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
| EA201892090A1 (ru) | АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ | |
| MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. |